2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchMeSH KeywordsGenetic CounselingGenetic TestingGerm CellsHealth Knowledge, Attitudes, PracticeHumansMaleProstatic NeoplasmsConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testing
2023
Genomic testing in voluntary workplace wellness programs in the US: Evidence and challenges
Cohn B, Ryan K, Hendy K, Callahan K, Roberts J, Spector‐Bagdady K, Mathews D, Blasco D, Crumpler N, Feero W, Ferber R, Giri V, Prince A, Sanghavi K, Uhlmann W, Vogle A, Lee C. Genomic testing in voluntary workplace wellness programs in the US: Evidence and challenges. Molecular Genetics & Genomic Medicine 2023, 11: e2245. PMID: 37592452, PMCID: PMC10655502, DOI: 10.1002/mgg3.2245.Peer-Reviewed Original Research
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchMeSH KeywordsAdultBreast NeoplasmsFemaleGenetic TestingHumansMaleOvarian NeoplasmsProstateProstatic NeoplasmsConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing
Loeb S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Wise D, Hollifield L, Brown L, Slater E, Pieczonka C, Gomella L, Kelly W, Trabulsi E, Handley N, Lallas C, Chandrasekar T, Mille P, Mann M, Mark J, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri V. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials 2022, 119: 106821. PMID: 35710085, DOI: 10.1016/j.cct.2022.106821.Peer-Reviewed Original ResearchMeSH KeywordsAccelerationGenetic CounselingGenetic TestingGerm CellsHumansMaleProstatic NeoplasmsTechnologyConceptsKey patient-reported outcomesGermline testingPatient-reported outcomesProstate cancerGenetic counselingCollaborative care strategiesProstate cancer careTwo-armed randomizedProstate Cancer FoundationEducation/counselingGermline evaluationGOV IDENTIFIERPrimary outcomeSecondary outcomesStudy armsTarget enrollmentAshkenazi Jewish ancestryCancer careFamily historyTumor featuresCancer FoundationCare strategiesDecisional conflictUS sitesPractice settingsGermline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing
Giri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanGenes, BRCA2Genetic TestingGerm CellsHumansMaleMiddle AgedProstatic NeoplasmsConceptsGermline testingAA menWhite menHereditary cancer assessmentStandard clinical testingCohort of menAfrican American menGermline evaluationMultivariable analysisClinical managementBorderline associationLP variantsVariant statusClinical testingGermline analysisPanel testingRate of variantsCare deliveryVariant spectrumGenetic testingCancer assessmentUncertain significanceDNA repair genesGenetic counselingAmerican menGuidelines on Germline Testing for Urologic Tumor Syndromes
Gomella P, Mark J, Giri V, Kelly W, Gomella L. Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus 2022, 8: 670-673. PMID: 35803854, DOI: 10.1016/j.euf.2022.06.010.Peer-Reviewed Original ResearchConceptsGermline testingCurrent guidelinesTumor syndromeTreatment of patientsScreening of patientsAvailability of testingDifferent organ systemsGenitourinary cancersGenitourinary tractUrologic cancersTreatment decisionsPatientsOrgan systemsGene mutationsCancerGenetic mutationsSyndromeFamily membersTreatmentGuidelinesMutationsTestingUse of geneticsTractGermline testing and genetic counselling in prostate cancer
Russo J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.Peer-Reviewed Original ResearchMeSH KeywordsGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingGerm CellsHumansMaleProstatic NeoplasmsConceptsProstate cancerCancer risk managementCancer riskGenetic testingHereditary cancer predisposition syndromesPre-test discussionUnique clinical featuresGermline pathogenic variantsPrecision medicineHealth care professionalsComplex management optionsAdditional cancer riskCancer predisposition syndromeHereditary cancer riskGenetic counsellingGermline testingMetastatic diseaseClinical featuresOptimal careMedical historyFamily historyPathogenic variantsPrecision therapyGene testingCancerGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansMalePrimary Health CareProstatic NeoplasmsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer riskWhen to use germline genetic testing in prostate cancer.
Giri V. When to use germline genetic testing in prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20: 78-81. PMID: 35120087.Commentaries, Editorials and Letters
2021
Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice
Giri V, Walker A, Gross L, Trabulsi E, Lallas C, Kelly W, Gomella L, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer 2021, 20: e104-e113. PMID: 35012874, DOI: 10.1016/j.clgc.2021.11.009.Peer-Reviewed Original ResearchMeSH KeywordsGenetic CounselingGenetic TestingHumansMaleProstatic NeoplasmsRadiation OncologistsUrologistsConceptsGermline testingFamily historyClinical practiceChronic Diseases frameworkMultiple family historyMaternal family historyCancer genetic testingMedical oncologistsAdvanced PCaPCa riskProvider interviewsAggressive PCaRadiation oncologistsPractice settingsGenetic testingLarger studyDisease frameworkClinical useOncologistsLower ratesPractice gapMenDescriptive statisticsPhiladelphia areaProvidersPredictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.
Giri V, Shimada A, Leader A. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precision Oncology 2021, 5: 1699-1708. PMID: 34778693, PMCID: PMC8585288, DOI: 10.1200/po.21.00231.Peer-Reviewed Original ResearchConceptsExact testCancer informationMultivariate logistic regression modelPopulation-based studyCross-sectional studyFisher's exact testPopulation-based sampleGenetic awarenessNational Trends SurveyNon-Hispanic whitesLogistic regression modelsPrecision medicine eraMiddle-high incomeDiverse population-based sampleCancer careModifiable factorsPersonalized cancer treatmentCancer preventionFemale genderHealth literacyCancer fatalismMedical literacyMultivariate analysisEthnic disparitiesGenetic testingAdopting Consensus Terms for Testing in Precision Medicine
Martin N, Tepper J, Giri V, Stinchcombe T, Cheng H, Javle M, Konnick E. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precision Oncology 2021, 5: 1563-1567. PMID: 34651094, PMCID: PMC8509918, DOI: 10.1200/po.21.00027.Peer-Reviewed Original ResearchConceptsGenetic testingTreatment decisionsOncology health care providersHealth care providersPrecision medicineLow socioeconomic statusPreferred termPatient advocacy groupsGermline testingTumor characteristicsOncology carePatient preferencesBiomarker testingPatient educationCancer riskCare providersPatient confusionSolid tumorsBlood cancersGermline mutationsGermline variantsAppropriate testingPatientsSocioeconomic statusGenomic testingGenetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care
Mark J, McDougall C, Giri V. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics Of North America 2021, 48: 311-322. PMID: 34210487, DOI: 10.1016/j.ucl.2021.03.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingProstate cancerGenetic testing guidelinesFirst-line therapyCastration-resistant diseaseEarly-stage diseaseProstate cancer careHealth care providersGenetic test resultsPCA careCancer careCare providersScreening settingCancer implicationsPARP inhibitorsTesting guidelinesPossible roleDiseaseCareMenPractice strategiesOncologistsTestingTherapyCancerPhiladelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.
Peters C, Turner C, Chesnut G, Giri V, Gomella L, Shriver C, Dobi A. Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. Canadian Journal Of Urology 2021, 28: 10659-10667. PMID: 34129457.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsGenetic Predisposition to DiseaseGenetic TestingHumansMaleMilitary MedicinePhiladelphiaProstatic NeoplasmsBarriers and facilitators of germline genetic evaluation for prostate cancer
Loeb S, Li R, Nolasco T, Byrne N, Cheng H, Becker D, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate 2021, 81: 754-764. PMID: 34057231, DOI: 10.1002/pros.24172.Peer-Reviewed Original ResearchConceptsCoordination of careProstate cancerChronic Diseases frameworkGuideline-concordant careGermline testingMedical oncologistsPatient factorsPhysicians' knowledgePhysician educationRadiation oncologistsPractice settingsDisease frameworkThematic saturationGenetic counselingGenetic evaluationCareOncologistsRecent dataCancerConstant comparative methodInterview guidePhysiciansNumerous barriersQualitative studyInterview transcripts
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsGenetic TestingGerm CellsGerm-Line MutationHumansMaleNeoplastic Syndromes, HereditaryProstatic NeoplasmsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelPractical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchMeSH KeywordsGenetic TestingGerm CellsGerm-Line MutationHumansMalePrecision MedicineProstatic NeoplasmsConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinicImplementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal Of Clinical Oncology 2020, 38: 2798-2811. PMID: 32516092, PMCID: PMC7430215, DOI: 10.1200/jco.20.00046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingFamily historyAdditional family historyHereditary cancer assessmentMetastatic disease treatmentAge 40 yearsClinical trial eligibilityPost-test discussionMultidisciplinary consensus conferenceProstate cancer treatmentMismatch repair genesCurrent practice challengesHereditary PCaTrial eligibilityMetastatic diseasePriority genesPathologic criteriaSomatic testingMetastatic PCaProstate cancerPCa diagnosisConsensus conferenceEvidence reviewCancer assessmentInformed consentCancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
Giri V, Hyatt C, Leader A. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice. Journal Of Urology 2020, 204: 1116-1118. PMID: 32926644, DOI: 10.1097/ju.0000000000001150.Peer-Reviewed Original Research